HANGZHOU TIGERMED CONSULTING (300347) H1 2025 earnings summary

Executive summary

• Revenue for H1 2025 was ¥3.25 billion, down 3.2% year-over-year; net profit attributable to shareholders fell 22.2% to ¥383 million.

• Adjusted net profit (excluding non-recurring items) dropped 67.1% year-over-year.

• Operating cash flow improved 130.4% year-over-year to ¥409 million, driven by better receivables collection.

• No interim dividend, bonus shares, or capital increase from reserves planned.

Financial highlights

• Gross margin declined from 39.1% to 29.4% due to lower clinical trial service margins.

• Main business income was ¥3.18 billion, with clinical trial technology services down 10.2% and related/lab services up 3.1%.

• Domestic revenue fell 10.1% while overseas revenue grew 4.6%.

• Total assets at period-end were ¥28.5 billion, down 0.6% from year-end 2024.

• Investment income contributed over half of total profit, mainly from associates and financial products.

Outlook and guidance

• Management expects domestic clinical trial operations to gradually recover as industry demand rebounds and legacy projects clear.

• Overseas clinical operations, especially in North America, are forecast to maintain strong growth.

• Continued focus on digitalization, AI, and global expansion to drive future growth.